Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Pembrolizumab with or without chemotherapy has become the standard therapy in advanced non-small cell lung cancer (NSCLC), with a fixed dose of 200mg every 3 weeks. The investigators performed this study to explore the clinical efficacy and safety of pharmacokinetic (PK)-guided pembrolizumab administration in advanced NSCLC.
Epistemonikos ID: b132d687d45d0cb06dfbb4032237c572461db6dc
First added on: May 10, 2024